Targeting the transforming growth factor-beta signaling pathway in human cancer.

PubWeight™: 1.57‹?› | Rank: Top 4%

🔗 View Article (PMC 2796203)

Published in Expert Opin Investig Drugs on January 01, 2010

Authors

Nagathihalli S Nagaraj1, Pran K Datta

Author Affiliations

1: Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Department of Surgery, Nashville, TN 37232, USA.

Associated clinical trials:

A Study of LY573636 in Treating Patients With Malignant Melanoma | NCT00383292

Articles citing this

The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol (2010) 3.57

Interaction of tumor cells with the microenvironment. Cell Commun Signal (2011) 1.38

Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug Des Devel Ther (2015) 1.33

Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol (2010) 1.27

TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer (2012) 1.27

Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis. Clin Cancer Res (2014) 1.17

Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum Reprod Update (2011) 1.10

Proteinase-activated receptors (PARs) - focus on receptor-receptor-interactions and their physiological and pathophysiological impact. Cell Commun Signal (2013) 1.06

TGF-β signaling and its targeting for glioma treatment. Am J Cancer Res (2015) 0.93

Therapeutic targeting of Neu1 sialidase with oseltamivir phosphate (Tamiflu®) disables cancer cell survival in human pancreatic cancer with acquired chemoresistance. Onco Targets Ther (2014) 0.92

Two faces of TGF-beta1 in breast cancer. Mediators Inflamm (2014) 0.92

Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host. Cancer Gene Ther (2012) 0.92

Molecular aspects of development and regulation of endometriosis. Reprod Biol Endocrinol (2014) 0.91

Elucidating the mechanism of regulation of transforming growth factor β Type II receptor expression in human lung cancer cell lines. Neoplasia (2011) 0.91

Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling. Oncotarget (2015) 0.89

D-glucuronyl C5-epimerase suppresses small-cell lung cancer cell proliferation in vitro and tumour growth in vivo. Br J Cancer (2011) 0.89

Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen. Br J Cancer (2013) 0.88

Synthesis and SAR of b-annulated 1,4-dihydropyridines define cardiomyogenic compounds as novel inhibitors of TGFβ signaling. J Med Chem (2012) 0.87

TGF-beta-dependent and -independent roles of STRAP in cancer. Front Biosci (Landmark Ed) (2011) 0.85

Specific-detection of clinical samples, systematic functional investigations, and transcriptome analysis reveals that splice variant MUC4/Y contributes to the malignant progression of pancreatic cancer by triggering malignancy-related positive feedback loops signaling. J Transl Med (2014) 0.83

DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-β-driven epithelial-mesenchymal transition. Cancer Discov (2013) 0.83

TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. Cancer Discov (2016) 0.82

TGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer. Clin Exp Metastasis (2013) 0.81

TGF-β signaling regulates fibrotic expression and activity in carpal tunnel syndrome. J Orthop Res (2014) 0.81

Interface between breast cancer cells and the tumor microenvironment using platelet-rich plasma to promote tumor angiogenesis - influence of platelets and fibrin bundles on the behavior of breast tumor cells. Oncotarget (2017) 0.81

EGFR/TGFα and TGFβ/CTGF Signaling in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets. Neuroendocrinology (2012) 0.80

Effects of Two Common Promoter Polymorphisms of Transforming Growth Factor-β1 on Breast Cancer Risks in Ahvaz, West South of Iran. Iran J Cancer Prev (2016) 0.80

Chemotherapeutic Targeting of the Transforming Growth Factor-β Pathway in Breast Cancers. Breast Cancer Manag (2015) 0.79

An epigenetic auto-feedback loop regulates TGF-β type II receptor expression and function in NSCLC. Oncotarget (2015) 0.79

MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC. Sci Rep (2015) 0.78

Metformin is a novel suppressor for transforming growth factor (TGF)-β1. Sci Rep (2016) 0.78

Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response. J Immunol Res (2016) 0.78

Transforming growth factor β signaling overcomes dasatinib resistance in lung cancer. PLoS One (2014) 0.78

Is there a place for inhibition of transforming growth factor-β and the polyol pathway in therapy for diabetic retinopathy? J Diabetes Investig (2010) 0.78

Recombinant fibromodulin has therapeutic effects on diabetic nephropathy by down-regulating transforming growth factor-β1 in streptozotocin-induced diabetic rat model. Iran J Basic Med Sci (2016) 0.78

DEAR1, a novel tumor suppressor that regulates cell polarity and epithelial plasticity. Cancer Res (2014) 0.78

Valproic acid inhibits irradiation-induced epithelial-mesenchymal transition and stem cell-like characteristics in esophageal squamous cell carcinoma. Int J Oncol (2016) 0.77

Molecular Aspects of Head and Neck Cancer Therapy. Hematol Oncol Clin North Am (2015) 0.77

Diosmetin induces apoptosis by upregulating p53 via the TGF-β signal pathway in HepG2 hepatoma cells. Mol Med Rep (2016) 0.77

Neuraminidase-1: a novel therapeutic target in multistage tumorigenesis. Oncotarget (2016) 0.77

Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo. BMC Cancer (2010) 0.77

TGFβ Pathway Inhibition Redifferentiates Human Pancreatic Islet β Cells Expanded In Vitro. PLoS One (2015) 0.76

Pre-clinical assessment of autologous DC-based therapy in ovarian cancer patients with progressive disease. Cancer Immunol Immunother (2012) 0.76

Histopathological Characteristics of Post-inflamed Coronary Arteries in Kawasaki Disease-like Vasculitis of Rabbits. Acta Histochem Cytochem (2016) 0.75

Association between transforming growth factor-β1 expression and the clinical features of triple negative breast cancer. Oncol Lett (2016) 0.75

TGF-β1 stimulates migration of type II endometrial cancer cells by down-regulating PTEN via activation of SMAD and ERK1/2 signaling pathways. Oncotarget (2016) 0.75

Ginsenoside Rd attenuates breast cancer metastasis implicating derepressing microRNA-18a-regulated Smad2 expression. Sci Rep (2016) 0.75

Therapeutic Targeting of Epithelial Plasticity Programs: Focus on the Epithelial-Mesenchymal Transition. Cells Tissues Organs (2017) 0.75

Concomitant underexpression of TGFBR2 and overexpression of hTERT are associated with poor prognosis in cervical cancer. Sci Rep (2017) 0.75

TGFβ upregulates PAR-1 expression and signalling responses in A549 lung adenocarcinoma cells. Oncotarget (2016) 0.75

TGF-β/ SMAD3 Pathway Stimulates Sphingosine-1-phosphate Receptor 3 Expression: Implication of Sphingosine-1-Phosphate Receptor 3 in Lung Adenocarcinoma Progression. J Biol Chem (2016) 0.75

Effects for Sequential Treatment of siAkt and Paclitaxel on Gastric Cancer Cell Lines. Int J Med Sci (2016) 0.75

Epithelial-mesenchymal transition in prostate cancer: an overview. Oncotarget (2017) 0.75

Molecular concept in human oral cancer. Natl J Maxillofac Surg (2015) 0.75

An optimized chromatographic strategy for multiplexing in parallel reaction monitoring mass spectrometry: Insights from quantitation of activated kinases. Mol Cell Proteomics (2016) 0.75

Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib. Yonsei Med J (2017) 0.75

Wnt/β-catenin signaling pathway inhibits the proliferation and apoptosis of U87 glioma cells via different mechanisms. PLoS One (2017) 0.75

Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine. J Assist Reprod Genet (2017) 0.75

Transforming Growth Factor-beta: A Therapeutic Target for Cancer. Hum Vaccin Immunother (2017) 0.75

Articles cited by this

(truncated to the top 100)

The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08

Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell (2003) 25.94

Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature (2003) 20.48

TGF-beta signal transduction. Annu Rev Biochem (1998) 17.83

TGFbeta in Cancer. Cell (2008) 17.44

Smad transcription factors. Genes Dev (2005) 13.43

Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest (2003) 12.56

Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98

Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol (2003) 11.12

TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23

SMAD proteins control DROSHA-mediated microRNA maturation. Nature (2008) 9.67

Making sense of latent TGFbeta activation. J Cell Sci (2003) 8.90

Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer (2006) 8.59

Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78

Non-Smad TGF-beta signals. J Cell Sci (2005) 6.06

Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell (2001) 5.84

A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev (1999) 5.13

Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest (2002) 4.64

Roles of TGFbeta in metastasis. Cell Res (2009) 4.35

Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol (2007) 4.28

Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell (1998) 4.22

Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A (2005) 4.20

TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell (2005) 3.75

Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta (2006) 3.64

Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell (2007) 3.55

Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol (2002) 3.52

Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov (2004) 3.47

LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther (2008) 2.99

Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev (2008) 2.95

Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol (2007) 2.75

Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta (2008) 2.72

TGF-beta receptor function in the endothelium. Cardiovasc Res (2005) 2.68

Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat Cell Biol (2004) 2.59

Regulation of cell proliferation by Smad proteins. J Cell Physiol (2002) 2.55

Defective repression of c-myc in breast cancer cells: A loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci U S A (2001) 2.55

Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor beta and bone morphogenetic protein. Mol Cell Biol (2004) 2.53

Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest (2007) 2.52

Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol (2005) 2.44

Cell adhesion protein receptors as targets for transforming growth factor-beta action. Cell (1987) 2.41

Lateral signaling enhances TGF-beta response complexity. Trends Cell Biol (2004) 2.38

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res (2004) 2.35

Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene (1999) 2.22

Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor. Science (1993) 2.20

Targeting the TGF beta signaling network in human neoplasia. Cancer Cell (2003) 2.16

Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J Biol Chem (2003) 2.12

Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology (2008) 2.07

Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res (2007) 1.89

A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability. Cancer Res (1995) 1.86

Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene (2005) 1.81

JNK regulates autocrine expression of TGF-beta1. Mol Cell (2004) 1.81

IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int (2006) 1.80

A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res (2007) 1.78

Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain. J Med Chem (2003) 1.72

The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Sci (2005) 1.67

Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res (2008) 1.64

Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res (2005) 1.62

Nucleocytoplasmic shuttling of Smad proteins. Cell Res (2009) 1.55

Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Exp Cell Res (2005) 1.53

Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci U S A (2004) 1.45

Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci (2007) 1.45

STRAP and Smad7 synergize in the inhibition of transforming growth factor beta signaling. Mol Cell Biol (2000) 1.45

Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther (2006) 1.43

Targeted disruption of Smad4 in mouse epidermis results in failure of hair follicle cycling and formation of skin tumors. Cancer Res (2005) 1.43

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides (2007) 1.40

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther (2005) 1.36

Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res (2006) 1.35

SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther (2004) 1.35

Evaluation of anti-TGF-beta2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci (2003) 1.33

Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition. PLoS One (2009) 1.33

Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res (2004) 1.29

Identification of STRAP, a novel WD domain protein in transforming growth factor-beta signaling. J Biol Chem (1998) 1.27

Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int J Cancer (1999) 1.27

Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res (2007) 1.27

The catalytic activity of the Src family kinases is required to disrupt cadherin-dependent cell-cell contacts. Mol Biol Cell (2000) 1.26

Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res (2006) 1.25

TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets (2006) 1.24

Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation (2005) 1.24

Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol (2003) 1.23

Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma. Cancer Res (1999) 1.21

Inactivation of TGF-beta signaling in hepatocytes results in an increased proliferative response after partial hepatectomy. Oncogene (2005) 1.20

A transforming growth factor beta-induced Smad3/Smad4 complex directly activates protein kinase A. Mol Cell Biol (2004) 1.19

Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells. Mol Cell Biol (2002) 1.18

Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells. Oncogene (2002) 1.16

TGF-beta inhibitors for the treatment of cancer. Expert Opin Investig Drugs (2005) 1.14

TGF-beta and cancer. Microbes Infect (1999) 1.14

A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Res (1999) 1.13

Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther (2002) 1.11

Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol (2007) 1.10

Loss of Smad4 expression predicts liver metastasis in human colorectal cancer. Oncol Rep (2007) 1.09

Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res (2001) 1.08

Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett (2009) 1.07

Transforming growth factor-beta1-dependent urokinase up-regulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. J Biol Chem (2003) 1.07

Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor. EMBO J (2001) 1.05

Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res (2008) 1.05

Selective inhibition of TGF-beta responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP. Oncogene (2005) 1.03

Involvement of c-Src kinase in the regulation of TGF-beta1-induced apoptosis. Oncogene (2004) 1.03

Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther (2004) 1.02

Involvement of cell-cell interactions in the rapid stimulation of Cas tyrosine phosphorylation and Src kinase activity by transforming growth factor-beta 1. J Biol Chem (2002) 1.01

Novel inactivating mutations of transforming growth factor-beta type I receptor gene in head-and-neck cancer metastases. Int J Cancer (2001) 1.00

Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients. Curr Opin Investig Drugs (2005) 1.00

Articles by these authors

A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia (2005) 2.16

Role of STRAP in regulating GSK3β function and Notch3 stabilization. Cell Cycle (2011) 1.54

Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Exp Cell Res (2005) 1.53

Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology (2009) 1.49

Smad4 regulates claudin-1 expression in a transforming growth factor-beta-independent manner in colon cancer cells. Cancer Res (2007) 1.19

Oncogenic function of a novel WD-domain protein, STRAP, in human carcinogenesis. Cancer Res (2006) 1.16

Stability of the Sp3-DNA complex is promoter-specific: Sp3 efficiently competes with Sp1 for binding to promoters containing multiple Sp-sites. Nucleic Acids Res (2003) 1.09

Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett (2009) 1.07

Smoking induces epithelial-to-mesenchymal transition in non-small cell lung cancer through HDAC-mediated downregulation of E-cadherin. Mol Cancer Ther (2012) 1.06

Transforming growth factor β induces expression of connective tissue growth factor in hepatic progenitor cells through Smad independent signaling. Cell Signal (2013) 1.05

Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta. J Biol Chem (2006) 1.01

Oncogenic serine-threonine kinase receptor-associated protein modulates the function of Ewing sarcoma protein through a novel mechanism. Cancer Res (2006) 0.98

Smad3 has a critical role in TGF-beta-mediated growth inhibition and apoptosis in colonic epithelial cells. J Surg Res (2004) 0.95

Role of Smad proteins in the regulation of NF-kappaB by TGF-beta in colon cancer cells. Cell Signal (2005) 0.94

Elucidating the mechanism of regulation of transforming growth factor β Type II receptor expression in human lung cancer cell lines. Neoplasia (2011) 0.91

Alterations in the Smad pathway in human cancers. Front Biosci (Landmark Ed) (2012) 0.89

Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. Hepatology (2014) 0.88

Phosphorylation of PNKP by ATM prevents its proteasomal degradation and enhances resistance to oxidative stress. Nucleic Acids Res (2012) 0.88

Smoking attenuates transforming growth factor-β-mediated tumor suppression function through downregulation of Smad3 in lung cancer. Cancer Prev Res (Phila) (2012) 0.87

TGF-beta-dependent and -independent roles of STRAP in cancer. Front Biosci (Landmark Ed) (2011) 0.85

Serine threonine receptor-associated protein (STRAP) plays a role in the maintenance of mesenchymal morphology. Cell Signal (2009) 0.83

Oncogenic STRAP functions as a novel negative regulator of E-cadherin and p21(Cip1) by modulating the transcription factor Sp1. Cell Cycle (2014) 0.81

Targeting the ERK pathway reduces liver metastasis of Smad4-inactivated colorectal cancer. Cancer Biol Ther (2013) 0.80

Smad6 suppresses the growth and self-renewal of hepatic progenitor cells. J Cell Physiol (2014) 0.80

Long-term smoking mediated down-regulation of Smad3 induces resistance to carboplatin in non-small cell lung cancer. Neoplasia (2012) 0.80

STRAP regulates c-Jun ubiquitin-mediated proteolysis and cellular proliferation. Biochem Biophys Res Commun (2011) 0.75